NIAID seeks to fund research that will identify changes in immune mechanisms and markers due to Mycobacterium tuberculosis exposure, infection, or disease in pediatric populations exposed to or infected with HIV-1.
We're looking for small businesses with promising radiological/nuclear medical countermeasures or biodosimetry devices that seek to further advance their products towards FDA licensure.
Apply if your research can explain how the immune system of a mother affects that of a fetus during gestation and beyond, and how cellular and humoral communication between the two affects fetal immune system development.
To continue supporting its grantee community in areas affected by Hurricanes Harvey, Irma, and Maria, NIH announced actions to relieve short-term administrative, financial management, and audit requirements.
Beginning January 25, 2019, you will need to include participants of all age ranges, including older adults, in human subjects research unless you have scientific or ethical reasons to exclude them.
NIH has lifted the pause on gain-of-function research anticipated to result in influenza, Middle East respiratory syndrome (MERS), or severe acute respiratory syndrome (SARS) viruses with enhanced pathogenicity or transmissibility in mammals via the respiratory route.
NIAID does not release noncompeting continuation awards until we’ve verified compliance with the Public Access Policy. While most investigators meet this requirement on time, some do not and the result is a funding delay.
Need a refresher on NIAID’s contracting terminology? Take our quiz, and pay close attention to explanations after each answer.
Here we cover types of patent applications, invention reporting requirements, and compliance advice.
NIAID will support multidisciplinary translational research centers focused on generating, validating, and advancing medical countermeasures to select NIAID Emerging Infectious Diseases and Pathogens.
Propose studies to understand mechanisms for regulating activation and function of human immune responses to infection, vaccination, and adjuvants.
To respond to contract solicitations—that is, requests for proposals and broad agency announcements—issued by NIAID on or after January 25, 2018, you’ll need to follow NIH’s new Clinical Trial Requirements for Grants and Contracts.
Check out new, well-written, top-scoring sample applications for the following activity codes: Academic Research Enhancement Award (R15), Small Business (R41, R42, R43, and R44), Research Scientist Development Award (K01), and Mentored Clinical Scientist Research Career Development Award (K08).
You have until January 31, 2018, to submit your annual report to NIH's Office of Laboratory Animal Welfare (OLAW).
Applicants targeting the January 7, 2018 receipt date, make sure you choose an active funding opportunity announcement and use FORMS-D.
NIAID recently launched a new and improved Resources for Researchers section on the NIAID website with a robust search tool to help you quickly find resources relevant to your research.
As you work on your next interim- or final-Research Performance Progress Report, keep in mind that the Project Outcomes section will be visible to the general public through NIH RePORTER.
Remember, you must send your interim- or final-Research Performance Progress Report (RPPR) within 120 calendar days after your grant's project period ends.
Funding recipients have the right to retain title to inventions made under federally funded research but must comply with regulations to ensure the timely transfer of the technology to the public sector.
NIAID plans to discontinue the funding opportunity announcement (FOA) NIAID Clinical Trial Implementation Grant (R01) and in its place use two new NIH clinical trial FOAs for investigator-initiated research.
Help find approaches to increase the precision and timeliness of measures along the HIV treatment cascade and determine critical components of rapid and sustained viral suppression at the individual and population level.
NIH is issuing (or reissuing) funding opportunity announcements with titles that specify whether clinical trials are optional, required, or not allowed.
NIAID sets interim paylines early in the fiscal year at a conservative level. Later in the fiscal year, once we better understand how many applications we’ve received and how much money is available, we adjust the paylines to their final levels.
Visit the NIAID Genomic Data Sharing policy page for in-depth coverage of when the policy applies, data submission and release, sample data sharing plans and templates, informed consent for sharing data from human samples, institutional certification, exceptions, and contact information.
If you’re an investigator, administrator, or anyone else new to the NIH grants process, the Regional Seminar offers a chance to gain a better perspective of NIH policies and programs, network with peers, and gather helpful NIH contacts.
NIH encourages authors to publish in journals that follow best practices promoted by professional scholarly publishing organizations for research integrity and ethics.
When you use an old application as the starting point for a new (A0) application, the A0 must not reference any prior applications or reviews—if it does, NIH will withdraw it without a review.
This opportunity supports multicomponent, multidisciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research, including extensive modeling of vaccine concepts in nonhuman primates.
I-Corps provides funding, mentoring, and networking opportunities to help active Phase I small business awardees commercialize promising biomedical technology through an eight-week, hands-on program.
NIH and its institutes will fund F&A costs for grants to foreign organizations and domestic grants with foreign components at a fixed rate of 8 percent of modified total direct costs, exclusive of tuition and related fees, direct expenditures for equipment, and subawards in excess of $25,000.
NIH is seeking feedback on areas of research limited by a lack of in-patient research beds, as well as areas of research best poised to utilize the Clinical Center’s unique in-patient resources more generally.
Big grants, clinical trials, multiproject research, and program project grants all require that you contact your program officer far in advance of your application due date.
The Final NIH Policy on the Use of a Single Institutional Review Board (sIRB) for Multi-Site Research requires an sIRB to conduct the ethical review required for the protection of human subjects whenever research projects using multiple domestic sites will conduct the same protocol involving non-exempt human subjects research.
If you have the expertise to identify the immune mechanisms required to induce and maintain durable protective immunity following immunization, consider a new funding opportunity announcement: Maintaining Immunity After Immunization.
Apply if your research can determine the mechanisms required for inducting and maintaining protective immunity in the elderly in response to infections and vaccinations, including the effects of chronic inflammation on those responses.
Deciding whether a study is or isn’t a clinical trial should not be the result of a scientific judgement call or even based on your prior experience. Rather, it should be determined using the Decision Tree for NIH Clinical Trial Definition.
The initiative provides eligible administrators access to good business practices for managing awards; assists the administrative staff in developing and implementing standard operating procedures for tracking grant expenditures and complying with NIH funding policies; and assists or trains other administrators in their local area.
OnPAR plays “matchmaker,” presenting your qualifying unfunded application's abstract to private biomedical foundations and pharmaceutical, biotech, and other life sciences companies that might be interested in funding your application.
Your proposal should foster new or expanded viral disease and immunology focused biomedical research collaborations between researchers in Japan and the Asia-Pacific region and U.S. investigators and institutions.
Read NIH’s new set of peer review criteria for training (T), fellowship (F), and career development (K) award applications that involve clinical trials submitted for due dates on or after January 25, 2018.
The 3rd International Conference on One Medicine One Science, or iCOMOS 2018, is a global forum for communicating the importance of science and policy at the interface of agriculture, environment, and medicine.